Viridian Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2012
Revenue	0.31	1.77	2.96	1.05	4.46	Upgrade
Revenue Growth (YoY)	-82.28%	-40.20%	182.19%	-76.46%	-46.80%	Upgrade
Gross Profit	0.31	1.77	2.96	1.05	4.46	Upgrade
Selling, General & Admin	95	35.18	25.81	13.27	11.65	Upgrade
Research & Development	159.77	100.89	56.89	28.3	34.79	Upgrade
Other Operating Expenses	0	0	0	69.86	0	Upgrade
Operating Expenses	254.76	136.08	82.69	111.43	46.44	Upgrade
Operating Income	-254.45	-134.3	-79.73	-110.38	-41.98	Upgrade
Interest Expense / Income	1.85	0.49	0	0.51	0.84	Upgrade
Other Expense / Income	-18.56	-4.92	-0.32	-0.17	-0.94	Upgrade
Pretax Income	-237.73	-129.87	-79.41	-110.72	-41.87	Upgrade
Net Income	-237.73	-129.87	-79.41	-110.72	-41.87	Upgrade
Shares Outstanding (Basic)	45	32	12	4	2	Upgrade
Shares Outstanding (Diluted)	45	32	12	4	2	Upgrade
Shares Change	39.48%	169.22%	235.07%	70.27%	5.87%	Upgrade
EPS (Basic)	-5.31	-4.05	-6.66	-31.13	-20.04	Upgrade
EPS (Diluted)	-5.31	-4.05	-6.66	-31.13	-20.04	Upgrade
Free Cash Flow	-185.07	-94.64	-54.84	-29.82	-36.14	Upgrade
Free Cash Flow Per Share	-4.13	-2.95	-4.60	-8.38	-17.30	Upgrade
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	Upgrade
Operating Margin	-81035.03%	-7579.23%	-2690.79%	-10512.38%	-941.02%	Upgrade
Profit Margin	-75711.46%	-7329.23%	-2680.16%	-10544.29%	-938.65%	Upgrade
Free Cash Flow Margin	-58938.85%	-5340.58%	-1850.83%	-2840.10%	-810.13%	Upgrade
EBITDA	-235.32	-129.1	-79.39	-109.97	-40.75	Upgrade
EBITDA Margin	-74941.72%	-7285.38%	-2679.45%	-10473.14%	-913.47%	Upgrade
Depreciation & Amortization	0.57	0.29	0.02	0.24	0.29	Upgrade
EBIT	-235.89	-129.39	-79.41	-110.21	-41.04	Upgrade
EBIT Margin	-75123.25%	-7301.81%	-2680.05%	-10495.90%	-919.93%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).